1206P HER2 copy number variation (CNV), HER2 expression and primary resistance mechanisms in patients (pts) with HER2-positive metastatic gastric or gastroesophageal junction cancer (mGC/GEJC) receiving first-line chemotherapy (CT) + trastuzumab (T) +/- pertuzumab (P) in the JACOB trial
In: Annals of Oncology, Jg. 33 (2022-09-01), S. S1100- (2S.)
Online
unknown
Zugriff:
Titel: |
1206P HER2 copy number variation (CNV), HER2 expression and primary resistance mechanisms in patients (pts) with HER2-positive metastatic gastric or gastroesophageal junction cancer (mGC/GEJC) receiving first-line chemotherapy (CT) + trastuzumab (T) +/- pertuzumab (P) in the JACOB trial
|
---|---|
Autor/in / Beteiligte Person: | Pietrantonio, F. ; Berrino, E. ; Manca, P. ; null S.E. Bellomo ; Raimondi, A. ; Corso, S. ; Morano, F. ; Migliore, C. ; Niger, M. ; Marchiò, C. ; M. Di Bartolomeo ; Restuccia, E. ; Lambertini, C. ; Tabernero, J. ; Giordano, S. |
Link: | |
Zeitschrift: | Annals of Oncology, Jg. 33 (2022-09-01), S. S1100- (2S.) |
Veröffentlichung: | Elsevier BV, 2022 |
Medientyp: | unknown |
ISSN: | 0923-7534 (print) |
DOI: | 10.1016/j.annonc.2022.07.1324 |
Schlagwort: |
|
Sonstiges: |
|